Abstract
This paper describes the performance characterization of the Extractive Membrane Bioreactor (EMB) when treating pharmaceutical industry process wastewater contaminated with Dichloromethane (DCM). EMB technology, which employs extraction and biodegradation in a single step, has proved a potential alternative for the treatment of harsh inorganic waste streams contaminated with organic compounds. It is particularly successful for the destruction of toxic Volatile Organic Compounds (VOCs) such as DCM without incurring air-stripping. A mixed culture was enriched to achieve complete biodegradation of DCM and total mineralization was confirmed by measurement of stoichiometric chloride release. The laboratory scale EMB was fed the process wastewater without any pre-treatment or dilution and was operated for 16 days with removals >95% for the entire period of operation. The applicability of the EMB to treatment of a range of pharmaceutical industry wastewaters and its costs are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
